Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Лечение гипергликемии при сахарном диабете 2-го типа, 2022: консенсусный доклад Американской диабетической ассоциации (ADA) и Европейской ассоциации по изучению диабета (EASD)
2022-09-23
SCID: 54.1/eudkq2gx
Discuss with AI
Cardiorenal protectionGlucagon-like peptide 1 receptor agonistsHyperglycemia managementSodium-glucose cotransporter 2 inhibitorsType 2 diabetes
Figures from the paper
Abstract (AI)
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Key Findings
1
Cardiovascular and kidney outcomes trials support broader recommendations for cardiorenal protection using SGLT2 inhibitors and GLP-1 receptor agonists in high-risk patients, including subgroup evidence.
2
The ADA and EASD updated consensus recommendations for managing hyperglycemia in adults with type 2 diabetes, based on publications since 2018.
3
The report summarizes consensus recommendations and provides practical implementation tips for the full diabetes care team.
4
The updated guidance expands attention to social determinants of health, health care systems, physical activity behaviors, and sleep.
5
Weight management receives greater emphasis as an integral component of holistic type 2 diabetes care.
Research Object
Management of hyperglycemia in adults with type 2 diabetes
Research Subject
consensus-based recommendations for holistic glycemic, weight, cardiovascular, and kidney-risk management, including the roles of social determinants, health care systems, physical activity, sleep, SGLT2 inhibitors, and GLP-1 receptor agonists
Publication Details
Publication Date
2022-09-23
Journal
Publisher
ISSN
Cited by
2387
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai9
World Health Organization 2020 guidelines on physical activity and sedentary behaviour2020
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes2015
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes2017
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes2016
Once-Weekly Semaglutide in Adults with Overweight or Obesity2021
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—20222021
Tirzepatide Once Weekly for the Treatment of Obesity2022
Advancing the global public health agenda for NAFLD: a consensus statement2021
5. Facilitating Behavior Change and Well-being to Improve Health Outcomes:Standards of Medical Care in Diabetes—20222021